Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: A meta-analysis

Chinese Medical Journal

Volumn 127, Issue 12, 2014, Pages 2376-2381

  Xue, Wen Rui ^a   Zhang, Qiang ^a   Xu, Yue ^a   Wang, Wei ^a   Zhang, Xiao Dong ^a   Hu, Xiao Peng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin inhibitor; Cardiovascular risk factors; Cyclosporine; Meta analysis; Metabolic syndrome; Post renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; CALCINEURIN;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; META ANALYSIS; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); OBESITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; CARDIOVASCULAR DISEASES; HYPERLIPIDEMIAS; METABOLIC SYNDROME X;

CALCINEURIN; CARDIOVASCULAR DISEASES; CYCLOSPORINE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 84902499452     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20140518     Document Type: Article

References (25)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
3. Mikolasevic I, Racki S, Lukenda V, Pavletic-Persic M, Milic S, Orlic L. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Med Hypotheses 2014; 82: 36-39.
4. Teixeira AP, Fernandes NM, Mata GF, Chaoubah A, Paula RB, Bastos MG. Prevalence of metabolic syndrome and its associated factors in renal transplant recipients. J Bras Nefrol. 2012; 34: 16-21.
5. Chen HZ, Zhu YH, Sui WG, Yan Q, Che WT, Zou GM, et al. Clinical study of the incidence and pathogenesis of metabolic syndrome after kidney transplantation (in Chinese). Int J Urol Nephrol 2008; 28: 293-296.
6. Salerno M P, Piselli P, Rossi E, Favi E, Gargiulo A, Spagnoletti G, et al. Metabolic syndrome and cardiovascular disease in kidney transplantation. Transplant Proc 2011; 43: 1067-1068.
7. Luan FL, Langewisch E, Ojo A. Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients. Clin Transplant 2010;24: 778-783.
8. Ozdemir FN, Karakan S, Akgul A, Haberal M. Metabolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009; 41: 2808-2810.
9. Bayer ND, Cochetti PT, Anil Kumar MS, Teal V, Huan Y, Doria C, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90: 861-866.
10. Hricik DE. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am SocNephrol 2011; 6: 1781-1785.
11. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.2 (2009) (updated September 2009). The Cochrane Collaboration. Available from: www.cochrane-handbook.org.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
13. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technol Assess 2003; 7: iii ix-x, 1-51.
14. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14: 370-383.
15. Hernández D, Alvarez A, Torres A, Oppenheimer F, Cobo M, González-Posada J, et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 2003; 35: 1727-1729.
16. Jurewicz WA. Tacrolimus versus cyclosporin immuno-suppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 Suppl 1: i7-i11.
17. Sui W, Zou H, Zou G, Yan Q, Chen H, Che W, et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl Immunol 2008; 20: 95-98.
18. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
19. Wang J, Kasiske B. Screening and management of pretransplant cardiovascular disease. Curr Opin Nephrol Hypertens 2010; 19: 586-591.
20. Deleuze S, Garrigue V, Delmas S, Chong G, Swarcz I, Cristol JP, et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? Transplant Proc 2006; 38: 2311-2313.
21. Busija DW, Miller AW, Katakam P, Simandle S, Erdös B. Mechanisms of vascular dysfunction in insulin resistance. Curr Opin Investig Drugs 2004; 5: 929-935.
22. Gluud LL. Bias in clinical intervention research. Am J Epidemiol 2006; 163: 493-501.
23. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983.
24. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104-1107.
25. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.